140 related articles for article (PubMed ID: 31832521)
41. [Clinicopathologic features and prognosis of gastrointestinal mantle cell lymphoma].
Hou WH; Wei P; Xie JL; Zheng YY; Zhang YL; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2018 Oct; 47(10):763-768. PubMed ID: 30317731
[No Abstract] [Full Text] [Related]
42. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
[TBL] [Abstract][Full Text] [Related]
43. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
44. Large cell variants of CD5+, CD23- B-cell lymphoma/leukemia.
Dunphy CH; Perkins SL
Arch Pathol Lab Med; 2001 Apr; 125(4):513-8. PubMed ID: 11260626
[TBL] [Abstract][Full Text] [Related]
45. [Effect of Carfilzomib on Proliferation and Apoptosis of Mantle Cell Lymphoma Cells].
Jiang GX; Li DY; Chen M; Liu YC; Chen JX; Shi XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):827-832. PubMed ID: 31204939
[TBL] [Abstract][Full Text] [Related]
46. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
47. Immunophenotypic Characterization of Canine Splenic Follicular-Derived B-Cell Lymphoma.
Stein L; Bacmeister C; Ylaya K; Fetsch P; Wang Z; Hewitt SM; Kiupel M
Vet Pathol; 2019 May; 56(3):350-357. PubMed ID: 30636524
[TBL] [Abstract][Full Text] [Related]
48. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
49. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
50. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
Liu Q; Alinari L; Chen CS; Yan F; Dalton JT; Lapalombella R; Zhang X; Mani R; Lin T; Byrd JC; Baiocchi RA; Muthusamy N
Clin Cancer Res; 2010 Jun; 16(12):3182-92. PubMed ID: 20460491
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
52. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
Williams ME; Connors JM; Dreyling MH; Gascoyne RD; Kahl BS; Leonard JP; Press OW; Wilson WH
Leuk Lymphoma; 2011 Jan; 52(1):24-33. PubMed ID: 21133727
[TBL] [Abstract][Full Text] [Related]
53. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.
Pham LV; Vang MT; Tamayo AT; Lu G; Challagundla P; Jorgensen JL; Rollo AA; Ou Z; Zhang L; Wang M; Ford RJ
Leuk Lymphoma; 2015 Jan; 56(1):186-93. PubMed ID: 24611650
[TBL] [Abstract][Full Text] [Related]
54. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.
Hanf M; Chiron D; de Visme S; Touzeau C; Maisonneuve H; Jardel H; Pellat-Deceunynck C; Amiot M; le Gouill S
BMC Cancer; 2016 Oct; 16(1):802. PubMed ID: 27737650
[TBL] [Abstract][Full Text] [Related]
55. Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
Asaad NY; Abd El-Wahed MM; Dawoud MM
J Egypt Natl Canc Inst; 2005 Dec; 17(4):279-90. PubMed ID: 17102815
[TBL] [Abstract][Full Text] [Related]
56. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
[TBL] [Abstract][Full Text] [Related]
58. Smoldering mantle cell lymphoma.
Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
[TBL] [Abstract][Full Text] [Related]
59. An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.
Inamdar AA; Loo A; Mikhail N; Lee P
Cureus; 2021 Aug; 13(8):e17598. PubMed ID: 34646650
[TBL] [Abstract][Full Text] [Related]
60. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
